An Emergency Medicine Broadsheet
·Phoenix·
Est. MMXXVI
Blue Fish Med · Today's Topic
Anaphylaxis Update
Anaphylaxis can progress from skin symptoms to airway obstruction or shock within minutes. Delayed epinephrine—not failure to give antihistamines—is the preventable failure most likely to cost a life.
Also known asanaphylactic reaction · anaphylactic shock · severe allergic reaction
A 29-year-old woman reaches the registration desk with red welts climbing her neck and a voice that has gone unexpectedly rough. Ten minutes earlier, she had been eating at a wedding; now she says her throat feels “tight,” and she is struggling to finish a sentence. Her blood pressure is falling as the waiting room watches. The next move is still yours.
— What’s your move? Read on.
Before you read
Which intervention cannot wait for IV access?
What features should determine observation time and disposition?
When to Think of It
Suspect anaphylaxis with sudden skin or mucosal involvement plus respiratory compromise or hypotension; involvement of two or more systems after a likely allergen; or hypotension after exposure to a known allergen. Skin findings may be absent. Hoarseness, stridor, wheeze, hypoxemia, syncope, and poor perfusion are danger signs.
Sick or Not Sick
The key call is whether there is airway, breathing, or circulatory compromise. If yes—or if symptoms are rapidly progressing—treat immediately; do not wait for a rash, laboratory testing, or IV access.
The First Fifteen Minutes
Suspected anaphylaxis: Epinephrine 0.3–0.5 mg IM (1 mg/mL solution) into the mid-anterolateral thigh; repeat every 5–15 minutes if airway, breathing, or circulatory symptoms persist. It reverses vasodilation, edema, and bronchospasm.
Hypotension or poor perfusion: Give 1–2 L isotonic crystalloid IV rapidly, reassessing and repeating as needed; capillary leak and vasodilation create profound intravascular depletion.
Persistent bronchospasm after epinephrine: Give albuterol 2.5–5 mg nebulized, repeat every 20 minutes as needed; it adds bronchodilation but does not replace epinephrine.
Refractory shock despite repeat IM epinephrine and fluids: Start epinephrine 1–10 mcg/min IV infusion, titrated in a monitored setting. Infusion preparation and dosing vary by protocol; check the institutional reference.
Beta-blocker use with refractory shock: Consider glucagon 1–5 mg IV over 5 minutes; if response, an infusion of 5–15 mcg/min IV may be used. Dosing varies; check a reference and anticipate vomiting.
Antihistamines are only for persistent skin symptoms after stabilization: cetirizine 10 mg PO, or diphenhydramine 25–50 mg PO/IV. For persistent urticaria, famotidine 20 mg PO/IV is an optional adjunct. None treats airway edema or shock.
Reassess voice, work of breathing, perfusion, and response after each intervention; summon airway expertise early if edema is progressing.
Definitive Care & Disposition
Remove the trigger if possible and involve airway/anesthesia support early for progressive upper-airway symptoms. Observe according to severity and response: longer observation or admission is appropriate after severe hypotension, airway involvement, repeated epinephrine, delayed response, or ongoing symptoms. Discharge only when stable, with an epinephrine autoinjector 0.3 mg IM device prescription (typically provide two), hands-on teaching, a written action plan, and allergy follow-up. Observation recommendations vary; use local guidance and individualize for biphasic-reaction risk. Corticosteroids have not been shown to reliably prevent biphasic reactions.
How This One Kills
Waiting for IV access—or giving antihistamines first—while laryngeal edema or shock progresses. The patient may lose the airway before the team recognizes that the first-line intervention was delayed.
The Differential — What Else Looks Like This
Isolated urticaria — No respiratory, cardiovascular, or significant gastrointestinal involvement; confusing it with anaphylaxis can lead to overtreatment, while missing progression can be dangerous.
Bradykinin-mediated angioedema — Often lacks urticaria and itching, and may occur with ACE-inhibitor use; assuming a histamine mechanism can delay airway planning and disease-specific treatment.
Vasovagal syncope — Bradycardia, pallor, and rapid improvement supine favor it over anaphylactic shock; confusing the two can delay epinephrine.
Acute asthma — Wheeze without a trigger-associated multisystem reaction favors asthma; treating wheeze alone misses evolving anaphylaxis.
The Second-Day Story
Older adults may present with syncope, weakness, or hypotension and have little or no rash; beta-blockers can blunt tachycardia, and early symptoms may be mistaken for a medication reaction or cardiac event. Look for abrupt onset after a plausible exposure, new hoarseness or wheeze, mucosal swelling, and a change from baseline perfusion. A normal skin exam does not rule it out.
Back to Our Patient
Back to our 29-year-old with the rough voice and rising welts: the sudden skin and mucosal findings with progressive throat symptoms and falling blood pressure meet the bedside threshold for anaphylaxis. The management fork is clear—she has airway and circulatory compromise—so give IM epinephrine immediately, repeat it if needed, and rapidly infuse crystalloid for persistent poor perfusion; prepare for early airway intervention if her voice or breathing worsens. Once stabilized, she needs monitored observation and admission if symptoms recur, repeated epinephrine is required, or airway concerns persist; discharge is appropriate only after sustained stability with autoinjectors, teaching, and follow-up.
Patient Presentation to Attending
How you’d present this patient on the floor — tight, pertinent positives and negatives, no rambling
“This is a 29-year-old woman with rapidly progressive rash, throat tightness, and hypotension after eating at a wedding. Ten minutes after eating, she developed pruritic welts and a hoarse voice, then became lightheaded; she has no known prior reaction or new medication exposure. She is tachycardic and hypotensive, with diffuse urticaria and hoarseness but no stridor or visible tongue swelling. Her oxygen saturation is 95% on room air, and her lungs have no wheeze. This is anaphylaxis with evolving upper-airway symptoms and circulatory compromise. I’m giving IM epinephrine now, starting rapid IV crystalloid, and reassessing airway and perfusion while preparing for early airway support. She will need monitored observation and admission if symptoms persist or recur.”
Study Directive
From memory, state the three clinical routes to diagnosing anaphylaxis and identify which one does not require skin findings.
Practice drawing the correct IM injection site and stating the adult dose, concentration, and repeat interval without prompting.
Run a two-minute scenario with a partner: one patient becomes hypotensive despite the first IM dose; verbalize reassessment, fluid resuscitation, repeat epinephrine, and escalation to an infusion.
Compare your institution’s observation and discharge guidance with a recognized emergency reference; write down the local criteria for extended observation and admission.
Golden DBK, Wang J, Waserman S, et al. · Ann Allergy Asthma Immunol, 2024 · PMID 38108678 · cited 347×
Give intramuscular epinephrine promptly, then tailor observation and discharge planning to the patient’s risk of recurrent symptoms.
More in Today's Issue
3 additional topics
2 of 4
Decision Pathways
Clinical decision pathways can reduce unnecessary admission and testing without accepting missed myocardial infarction—but only when applied to the right...
A 54-year-old man sits upright on the edge of the stretcher, one hand pressed to the center of his chest. The pressure began while he was carrying groceries and eased after he stopped; his first ECG is on the screen, and the first blood sample is already in the lab. He asks whether he can go home before his parking meter expires. One more result—and the pathway it belongs to—are still pending.
Before You Read
When can a validated pathway safely support discharge after chest pain?
What does a “rule-out” result fail to rule out?
Which patient should bypass the pathway and move directly to an urgent intervention?
Why It Matters
Clinical decision pathways can reduce unnecessary admission and testing without accepting missed myocardial infarction—but only when applied to the right patient, with the correct assay and timing. A score is not a substitute for recognizing instability or ongoing ischemia.
When to Think of It
This brief focuses on ED chest-pain pathways for possible acute coronary syndrome (ACS). Use a validated high-sensitivity troponin pathway—such as a local 0/1-hour or 0/2-hour algorithm—when the patient is clinically stable and the presentation is appropriate. Obtain and interpret an ECG promptly; repeat it for recurrent symptoms or evolving concern. Do not use a pathway to dismiss a STEMI, unstable patient, or another immediately dangerous diagnosis.
Sick or Not Sick
The central decision is whether the patient has an immediate high-risk feature that requires treatment/admission, or is appropriate for a validated rule-out pathway. Concerning ECG changes, hemodynamic instability, ongoing/recurrent ischemic symptoms, or a significant troponin rise should override a reassuring score.
The First Fifteen Minutes
Obtain a focused history, vital signs, cardiac monitor, and 12-lead ECG; repeat ECGs if pain returns or the clinical picture changes. Send high-sensitivity troponin at the pathway-specified time points, not at arbitrary intervals.
Possible ACS without a contraindication: Give aspirin 162–325 mg PO, chewed once; it inhibits platelet aggregation while the diagnostic evaluation proceeds.
Ongoing ischemic discomfort with adequate blood pressure and no recent phosphodiesterase-5 inhibitor use or suspected right-ventricular infarction: Give nitroglycerin 0.4 mg SL every 5 minutes, up to 3 doses; it reduces preload and myocardial oxygen demand. Withhold for hypotension or relevant contraindication.
Do not let a low-risk score delay escalation for a concerning ECG, clinical deterioration, or a troponin result above the assay-specific threshold. Check the pathway’s assay, timing, and delta criteria.
Definitive Care & Disposition
Apply the pathway as validated locally: it typically combines clinical assessment, ECG, and serial assay-specific high-sensitivity troponins. Patients meeting rule-out criteria, with reassuring reassessment and no alternate emergency diagnosis, may be discharged with clear return precautions and timely follow-up; routine urgent stress testing is not required for every low-risk patient. Patients in an intermediate zone need further observation, repeat testing, and individualized testing or consultation. High-risk findings, dynamic ECG changes, significant troponin change, or ongoing ischemia warrant admission and ACS-directed care. A “rule-out” pathway addresses MI risk; it does not rule out pulmonary embolism, aortic catastrophe, or other causes of chest pain.
How This One Kills
Treating the pathway output as a diagnosis. A patient with ongoing ischemic symptoms or a changing ECG can be high risk despite an initially low troponin; conversely, an elevated troponin signals myocardial injury, not automatically type 1 MI.
The Atypical Presentation
Older adults, people with diabetes, and some women may have dyspnea, fatigue, nausea, syncope, or vague discomfort rather than classic pressure. A quiet history or non-diagnostic first ECG does not establish low risk. Use the same validated serial testing approach, but let the overall clinical picture, symptom timing, comorbidities, and evolving ECG guide whether the patient truly fits the pathway.
Back to Our Patient
Back to our 54-year-old with pressure while carrying groceries: he is stable, his ECG has no ischemic changes, and repeat ECG remains unchanged. His serial high-sensitivity troponins meet the local validated rule-out criteria, with values below the assay-specific thresholds and no significant delta; reassessment shows no recurrent symptoms or finding that suggests another emergency diagnosis. He is appropriate for discharge through the pathway, with return precautions and timely follow-up—not because one number or score “cleared” him, but because the complete validated sequence and clinical reassessment support low short-term risk.
Patient Presentation to Attending
“This is a 54-year-old man with exertional central chest pressure that resolved with rest. It began while he was carrying groceries about five hours ago; he has no syncope, dyspnea, pleuritic pain, or recurrent symptoms. He is hemodynamically stable, and his ECG shows no ischemic changes; repeat ECG is unchanged. Serial high-sensitivity troponins meet our local rule-out criteria, with no significant delta. He has no concerning finding on focused reassessment to suggest another acute cause. He is low risk by the validated chest-pain pathway, and I recommend discharge with return precautions and timely follow-up.”
Study Directive
Find your ED’s exact high-sensitivity troponin pathway; record the assay, sampling times, rule-out criteria, and intermediate-zone action.
Work through three sample cases: one rule-out, one intermediate, and one rule-in. For each, state the next action and why the pathway does or does not apply.
Practice a one-minute handoff that includes symptom timing, ECG, serial troponin values and deltas, pathway category, reassessment, and disposition.
Key Medications
Suspected ACS without contraindication: aspirin 162–325 mg PO, chewed once.
Ischemic discomfort when blood pressure and contraindications permit: nitroglycerin 0.4 mg SL every 5 minutes, up to 3 doses. Avoid with hypotension, suspected right-ventricular infarction, or recent phosphodiesterase-5 inhibitor use; specific safe intervals depend on the agent.
Additional antithrombotic treatment depends on the working diagnosis and local ACS protocol; do not start it solely because a pathway score is elevated.
High-Yield Pearls
Troponin is a marker of myocardial injury; the diagnosis of MI also requires clinical evidence of ischemia.
A pathway is only as reliable as its assay-specific cutoffs and correctly timed blood draws.
A new or dynamic ECG finding should trigger reassessment even when an earlier troponin was reassuring.
The Mimics
Pulmonary embolism — Pleuritic pain, hypoxemia, or venous thromboembolism risk may redirect the workup; attributing these to ACS can miss obstructive shock.
Aortic dissection — Abrupt maximal pain, pulse/BP asymmetry, or neurologic deficit demands urgent evaluation; antithrombotic treatment for presumed ACS may be harmful.
Pericarditis — Positional/pleuritic pain and diffuse rather than territorial ECG changes favor it; confusing it with ACS can lead to unnecessary invasive treatment.
Reflux or chest-wall pain — Reproducibility or meal association may support these diagnoses but does not, alone, exclude ACS; premature closure risks a missed event.
Board Question
A stable patient with chest discomfort has a non-ischemic ECG and an initial high-sensitivity troponin below the assay’s rule-out threshold. What is the best next step?
ADischarge based on the initial troponin alone
BApply a locally validated serial troponin pathway at its specified time points
CDiagnose non-cardiac pain because the ECG is non-ischemic
DOrder urgent stress testing for every patient before discharge
Reveal answer
Correct: B
A single initial result is not sufficient unless a specific, validated pathway supports that use for the patient’s symptom timing and assay. Serial testing and clinical reassessment help identify evolving injury while avoiding unnecessary testing in appropriately ruled-out patients.
3 of 4
Hemophagocytic Lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that can resemble sepsis while rapidly causing multiorgan failure....
Also known asHLH · hemophagocytic syndrome · macrophage activation syndrome
A 41-year-old man is brought in after three days of worsening fever and confusion. His skin is hot, his eyes are yellow at the edges, and his partner says he has been “getting sicker every day” despite treatment for a recent infection. His blood counts are low, his liver tests are rising, and the team is deciding whether this is ordinary sepsis or something more. The next blood draw is still being arranged.
Before You Read
What combination of findings should raise concern for HLH?
Which result is suggestive but not diagnostic?
When should treatment for a suspected hyperinflammatory syndrome begin alongside infection management?
Why It Matters
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that can resemble sepsis while rapidly causing multiorgan failure. Waiting for every diagnostic criterion to be fulfilled can delay lifesaving specialist-directed therapy.
When to Think of It
Think HLH in persistent fever with cytopenias and progressive liver, coagulation, neurologic, or other organ dysfunction—especially when the course seems disproportionate to, or fails to improve with, treatment for an apparent trigger. Clues include splenomegaly, high ferritin, hypertriglyceridemia, low fibrinogen, elevated soluble IL-2 receptor, and impaired NK-cell function. Triggers include infection, malignancy, and autoimmune disease. Ferritin can be markedly elevated but is not diagnostic by itself.
Sick or Not Sick
The critical call is whether the patient has progressive organ dysfunction with a credible HLH pattern. In a deteriorating patient, urgently involve hematology and critical care while evaluating and treating plausible infection; do not wait for marrow hemophagocytosis or completion of all HLH-2004 criteria.
The First Fifteen Minutes
Stabilize airway, breathing, and circulation; obtain CBC with differential, CMP, coagulation studies, fibrinogen, triglycerides, ferritin, LDH, blood cultures, and type and screen. Add soluble IL-2 receptor and other specialized testing in coordination with consultants; do not delay care for results.
If sepsis or neutropenic infection is suspected: Draw cultures if this causes no meaningful delay, then give cefepime 2 g IV (renal-adjusted; repeat dosing commonly every 8 hours) for broad antipseudomonal coverage. Add vancomycin 20–25 mg/kg IV loading dose (maximum 3 g) only when indicated by the clinical picture and local protocol; it adds resistant gram-positive coverage. Subsequent vancomycin dosing should follow local monitoring guidance.
Progressive organ-threatening illness with high clinical suspicion after urgent specialist discussion: Dexamethasone 10 mg/m² IV or PO daily is a commonly used HLH-directed starting regimen; it suppresses the pathologic inflammatory response. The regimen is specialist-directed and may need modification for the trigger and patient.
Etoposide is not an automatic ED dose: if hematology recommends HLH-94–type therapy, a commonly used dose is 150 mg/m² IV on the protocol schedule, with adjustment for organ function and specialist oversight. Regimen details vary; check an authoritative dosing reference and institutional protocol.
Definitive Care & Disposition
Admit patients with suspected HLH; ICU care is indicated for shock, respiratory failure, encephalopathy, or rapidly evolving organ dysfunction. Hematology leads treatment and evaluation of the trigger. Diagnostic frameworks include HLH-2004 criteria and the HScore; obtain ferritin, triglycerides, fibrinogen, soluble IL-2 receptor, and NK-cell testing as available, and pursue marrow or tissue evaluation when appropriate. Treatment may include dexamethasone and etoposide, with additional trigger-specific or immune-directed therapy chosen by specialists. Continue appropriate infection evaluation and treatment; HLH and infection can coexist.
How This One Kills
Calling the entire picture “sepsis” and waiting for cultures, marrow findings, or a very high ferritin to settle the diagnosis while inflammation drives progressive organ failure. Conversely, treating one elevated ferritin value as proof can obscure infection, malignancy, or another cause.
The Atypical Presentation
Older or immunocompromised patients may have blunted fever, few classic inflammatory signs, or an apparent infection that partially responds to antibiotics while organ dysfunction continues. Cytopenias may emerge over time rather than appearing together initially, and ferritin elevation is nonspecific. Follow the trajectory: persistent fever or deterioration, falling counts, worsening liver/coagulation abnormalities, and a plausible trigger should prompt early specialist discussion and repeat evaluation.
Back to Our Patient
Back to our 41-year-old with fever, jaundice, confusion, and falling blood counts: persistent fever with cytopenias and progressive liver and neurologic dysfunction makes HLH a critical consideration, not a diagnosis to postpone until every test returns. His immediate fork is deterioration with possible infection, so stabilize him, obtain cultures and HLH-directed studies, and start empiric antibiotics if infection is suspected; involve hematology and critical care urgently. Given progressive organ-threatening illness and high suspicion, discuss prompt specialist-directed dexamethasone while the diagnostic workup continues. He requires admission to a closely monitored setting, with ICU care if his organ dysfunction is severe or worsening.
Patient Presentation to Attending
“This is a 41-year-old man with three days of fever and progressive confusion, now with jaundice and worsening laboratory abnormalities. He was recently treated for a presumed infection but has continued to deteriorate; his partner reports no new medications or known immunosuppression. He is febrile and confused, with scleral icterus and no clear focal source on initial assessment. His CBC shows cytopenias, and his liver tests are rising; HLH studies and cultures are pending. I’m concerned for HLH with evolving organ dysfunction, while keeping concurrent sepsis in the differential. I’m arranging admission with close monitoring, obtaining cultures and key HLH studies, and starting empiric antibiotics if infection is suspected. I’ll involve hematology and critical care now to decide on early immunosuppression.”
Study Directive
From memory, list the eight HLH-2004 criteria and the minimum number required for the traditional criteria-based diagnosis.
Review how the HScore weights fever, organomegaly, cytopenias, ferritin, triglycerides, fibrinogen, AST, immunosuppression, and marrow findings.
Use a practice case to build a one-minute consult request: trigger, trajectory, cytopenias, organ dysfunction, key HLH labs, and the decision needed now.
Check your institution’s critical-care, hematology, and antimicrobial pathways for how suspected HLH and possible sepsis are managed in parallel.
Key Medications
Suspected sepsis/neutropenic infection: cefepime 2 g IV, commonly every 8 hours with renal adjustment.
Add-on vancomycin when indicated: 20–25 mg/kg IV loading dose, maximum 3 g; subsequent dosing per local monitoring protocol.
Common HLH-94–type dexamethasone starting dose: 10 mg/m² IV/PO daily; specialist and protocol dependent.
Etoposide, if selected by hematology: commonly 150 mg/m² IV on the HLH protocol schedule; renal adjustment and protocol details vary. Check a dosing reference and institutional protocol.
High-Yield Pearls
A falling fibrinogen in a febrile patient with cytopenias and liver dysfunction is a particularly concerning clue.
A very high ferritin increases suspicion, but its diagnostic value depends on the whole clinical pattern and trajectory.
Finding an infection does not close the case: infection can trigger or coexist with HLH.
The Mimics
Sepsis — A clear infectious source and improvement with appropriate therapy may support it, but sepsis and HLH can coexist; assuming one excludes the other can leave either untreated.
Acute leukemia — Abnormal blasts on smear or marrow point toward a primary hematologic malignancy; missing concurrent HLH may underestimate the inflammatory emergency.
Thrombotic microangiopathy — Microangiopathic hemolysis and schistocytes are discriminating clues; mistaking it for HLH can delay urgent disease-specific management.
Macrophage activation syndrome — A closely related hyperinflammatory syndrome, often with rheumatologic disease; confusing labels can distract from the urgent need for specialist-directed control of inflammation and the trigger.
Board Question
A patient has persistent fever, cytopenias, worsening liver dysfunction, and markedly elevated ferritin. Which statement is most accurate?
AFerritin alone establishes HLH
BBone marrow hemophagocytosis must be present before HLH can be considered
CHLH can coexist with infection, and deteriorating patients need urgent specialist evaluation
DHLH should be excluded if blood cultures are positive
Reveal answer
Correct: C
Ferritin is a useful clue but is not diagnostic, and hemophagocytosis is not required to begin considering the syndrome. Infection does not exclude HLH, and treatment decisions in a deteriorating patient should not wait for every criterion.
Suspect HLH in a persistently febrile, deteriorating patient with cytopenias and marked hyperferritinemia, and involve hematology early because treatment should not wait for every diagnostic criterion to be met.
4 of 4
Blast Crisis
Blast-phase leukemia can progress quickly, while leukostasis and tumor lysis can cause respiratory, neurologic, renal, and cardiac injury. The immediate...
Also known asCML blast crisis · leukemic transformation · acute leukemia transformation
A 62-year-old man with a history of a blood disorder arrives short of breath, blinking through blurred vision. His breathing is fast, his hands are cool, and the monitor shows a heart rate of 122. The automated blood count flags an extreme white-cell result, and the smear is being rushed to the lab. The cause of the worsening symptoms is not yet clear.
Before You Read
What makes an extreme white-cell count an emergency rather than a number to observe?
Which organ-system symptoms suggest leukostasis?
What should happen while definitive hematologic classification is pending?
Why It Matters
Blast-phase leukemia can progress quickly, while leukostasis and tumor lysis can cause respiratory, neurologic, renal, and cardiac injury. The immediate threat is clinical leukostasis and organ dysfunction—not simply crossing a white-cell threshold.
When to Think of It
Suspect blast-phase CML in a patient with known or possible chronic myeloid leukemia (CML) who has rapidly progressive symptoms or circulating blasts. A blast phase is commonly defined by at least 20% blasts in blood or marrow, or extramedullary blast proliferation; classification criteria can vary, so confirm with hematology. Hyperleukocytosis is often defined as WBC above 100,000/µL, but leukostasis is a clinical syndrome: dyspnea/hypoxemia, neurologic change, visual symptoms, or other end-organ dysfunction in the setting of marked leukocytosis.
Sick or Not Sick
The decision that matters most is whether symptomatic leukostasis or other acute organ dysfunction is present. If yes, treat as a hematologic emergency and involve hematology and critical care immediately; do not wait for the final marrow diagnosis. A high count without symptoms is not, by itself, an indication for leukapheresis.
The First Fifteen Minutes
Stabilize ABCs; assess oxygenation, neurologic status, and perfusion. Obtain CBC with differential and smear, CMP, potassium, phosphate, calcium, uric acid, LDH, coagulation studies, type and screen, and ECG; arrange urgent hematology consultation.
High tumor-lysis risk or laboratory evidence of lysis: Start isotonic IV fluids, commonly 200–300 mL/hour in adults if cardiac and renal status allow; individualize to avoid overload. Avoid routine urine alkalinization.
Tumor-lysis risk without established hyperuricemia requiring urate oxidase: Give allopurinol 300 mg PO daily (or institutionally specified divided dosing), adjusted for renal function; it limits new uric-acid formation. Dosing varies by protocol and renal function.
Established hyperuricemia or very high tumor-lysis risk: Consider rasburicase 0.15–0.2 mg/kg IV once, with repeat dosing guided by uric acid and protocol. It rapidly degrades uric acid; do not use in known G6PD deficiency, and check institutional guidance.
Symptomatic leukostasis or rapidly rising blast burden, after immediate hematology discussion: Hydroxyurea 50–100 mg/kg/day PO in divided doses is a commonly used cytoreductive range; dose and titration are specialist- and protocol-dependent, so verify with a dosing reference. Do not delay urgent consultation while arranging it.
Avoid reflexive red-cell transfusion for anemia in leukostasis unless clinically necessary; increased viscosity can worsen microvascular flow. If transfusion is needed, coordinate with hematology.
Definitive Care & Disposition
Admit urgently, often to an ICU or closely monitored hematology service when leukostasis, respiratory compromise, neurologic symptoms, or metabolic derangements are present. Hematology determines disease phase and directs cytoreduction and definitive leukemia treatment, which may include a tyrosine kinase inhibitor and phase-appropriate chemotherapy. Monitor and treat tumor lysis, DIC, bleeding, infection, and renal injury; leukapheresis is considered selectively and should not delay pharmacologic cytoreduction or definitive therapy. The preferred approach depends on subtype, symptoms, and local expertise.
How This One Kills
Treating a markedly elevated WBC as a lab abnormality rather than recognizing symptomatic leukostasis—or delaying cytoreduction and specialist care while waiting for confirmatory tests. Pulmonary or cerebral microvascular injury can worsen rapidly.
The Atypical Presentation
Older adults may report fatigue, falls, headache, or vague breathlessness rather than dramatic neurologic or respiratory symptoms. Patients with CML may have a known diagnosis but incomplete follow-up, and the count may be extreme before classic signs are obvious. Compare with prior counts, examine the smear, ask specifically about visual and neurologic changes, and let evolving symptoms—not a reassuring appearance or count alone—set the urgency.
Back to Our Patient
Back to our 62-year-old with cool hands, rapid breathing, and blurred vision: the extreme white-cell count plus respiratory and visual symptoms raises immediate concern for leukostasis, while the smear and marrow evaluation establish the disease phase. The key fork is symptomatic organ dysfunction, so stabilize him, urgently involve hematology, assess for leukostasis and tumor lysis, and begin carefully monitored hydration and protocol-directed cytoreduction without waiting for final classification. He needs urgent admission to a closely monitored hematology or critical-care setting for definitive treatment and surveillance for metabolic complications.
Patient Presentation to Attending
“This is a 62-year-old man with a history of a myeloproliferative blood disorder, presenting with acute dyspnea and blurred vision. The symptoms have worsened today; he has no reported chest pain or focal weakness. He is tachycardic and tachypneic, with cool hands and new visual symptoms. His CBC flags extreme leukocytosis, and the peripheral smear is pending. I’m concerned for symptomatic leukostasis in blast-phase leukemia, with tumor lysis risk. I’ve requested urgent hematology and critical-care evaluation, sent tumor-lysis studies, and am preparing for monitored hydration and specialist-directed cytoreduction. He needs immediate admission for definitive management.”
Study Directive
Write down the current blast-phase threshold used by your institution and one feature that differentiates CML blast phase from chronic phase.
Practice a focused leukostasis exam: respiratory status, mental status, focal deficits, and visual symptoms.
From memory, list the initial tumor-lysis labs and identify the classic direction of change for potassium, phosphate, uric acid, calcium, and creatinine.
Ask your hematology service how it handles hydroxyurea, leukapheresis, and transfusion in suspected leukostasis; record the local escalation pathway.
Key Medications
Cytoreduction after urgent hematology consultation: hydroxyurea 50–100 mg/kg/day PO in divided doses is a commonly used range; dosing is protocol-dependent and requires specialist oversight.
Tumor-lysis prevention when appropriate: allopurinol 300 mg PO daily, adjusted for renal function and local protocol.
Hyperuricemia or very high tumor-lysis risk: rasburicase 0.15–0.2 mg/kg IV once, with repeat dosing guided by protocol; contraindicated in known G6PD deficiency. Dose and repeat strategy vary—check an institutional reference.
IV isotonic crystalloid, if tolerated: commonly 200–300 mL/hour, individualized to cardiac and renal status.
High-Yield Pearls
In CML, splenomegaly and a myeloid left shift do not themselves establish blast phase; the blast proportion and extramedullary blast disease matter.
New visual symptoms, hypoxemia, or neurologic change with marked leukocytosis should prompt concern for leukostasis even before the smear is finalized.
Leukostasis risk is driven by cell type and clinical condition, not a single universal WBC cutoff.
The Mimics
Severe infection with leukemoid reaction — A left shift without a blast population and an infectious source support a reactive process; mistaking it for blast-phase disease can delay infection treatment.
Chronic-phase CML with high mature-cell count — Predominantly mature granulocytes without blast-phase criteria distinguish it; misclassification can prompt inappropriate therapy.
Tumor lysis syndrome — Potassium, phosphate, uric acid, calcium, and renal abnormalities define the metabolic emergency; focusing only on leukostasis can miss rapidly lethal electrolyte complications.
DIC — Abnormal coagulation with bleeding or thrombosis can accompany leukemia but requires its own monitoring and supportive care; overlooking it risks catastrophic hemorrhage.
Board Question
A patient with suspected blast-phase leukemia has marked leukocytosis, new dyspnea, and visual changes. Which statement best guides immediate management?
AWait for marrow confirmation before involving hematology
BThe WBC value alone establishes leukostasis and mandates leukapheresis
CTreat the symptoms as possible leukostasis and urgently involve hematology while evaluating for tumor lysis
DTransfuse red cells liberally to improve oxygen delivery
Reveal answer
Correct: C
Leukostasis is a clinical diagnosis of end-organ dysfunction in the setting of marked leukocytosis; urgent specialist-directed cytoreduction should not wait for final classification. Leukapheresis is not automatic based on count alone, and red-cell transfusion may worsen viscosity.
CML blast phase requires urgent hematology involvement to guide tyrosine kinase inhibitor–based treatment, acute-leukemia therapy, and transplant evaluation.
Yesterday’s Differential
The daily puzzle — from editions past
A quick test of recall from prior editions. Commit to an answer before you check.
From yesterday's edition
A 70-year-old woman with hypertension and aortic stenosis presents with chest pressure. Her vitals are stable. What’s the diagnosis, and the first move?
Check your answer
Left Bundle Branch Block. In a chest-pain patient with LBBB, don't stop at the block — measure ST shifts against QRS proportions and apply Sgarbossa/excessive-discordance criteria; concordant ST change or excessive discordance drives emergent cath lab activation, while an old LBBB with only appropriate discordance directs you to serial troponins and an alternative workup.
From the October 5 edition
Today, three days ago: Pralidoxime (2-PAM). What’s the adult ED dose, and the contraindication you’d most regret missing?
Check your answer
1–2 g IV over 15–30 min, then infusion commonly 500 mg/h or repeated dosing per toxicology/protocol. Pediatric dosing weight-based. No absolute contraindication in severe organophosphate poisoning.
From the September 28 edition
A patient at 30 weeks’ gestation has cardiac arrest. CPR and ACLS are underway, but ROSC has not occurred. The uterine fundus is above the umbilicus. What is the best next step?
ATransfer to the operating room before delivery
BWait for fetal monitoring to determine viability
CBegin resuscitative hysterotomy at the site of arrest
DWithhold epinephrine because of fetal risk
Reveal answer
Correct · C
Prepare immediately and begin resuscitative hysterotomy if ROSC has not occurred, aiming for delivery by 5 minutes. Do not delay for transfer or fetal assessment; standard ACLS medications remain indicated.
Journal Watch
From the FOAMed wire
Notable posts and reviews from the last week, ranked by relevance to today’s lead and source trust.
Free up ICU beds and reduce patient harm. Learn how emergency physicians can safely identify candidates and manage ventilator liberation in the ED. The post Extubation in the Emergency Department appeared first on ACEP Now .
How to resolve bedside discordance in the emergency department to prevent harm. The post Missed Pediatric Shock: Vital Signs Versus Clinical Gestalt appeared first on ACEP Now .
Podcast Picks
Two for the shift
Critical Care Perspectives in Emergency Medicine2026-09-01
Brain damage and death from ischemic encephalopathy is common after cardiac arrest. Animal studies and limited observational studies suggest that high oxygen exposure after ROSC may result in neuronal death. As such, it is hypothesized that limiting oxygen exposure (conservative oxygen) many attenuate reperfusion injury and improve outcomes. At present,...
Source
Critical Care Perspectives in Emergency Medicine
Published
2026-09-01
Host
Critical Care Perspectives in Emergency Medicine, Critical Care Perspectives in Emergency Medicine
Epistaxis is usually straightforward—until it isn’t. How can you distinguish an anterior bleed from a dangerous posterior bleed? What’s the best sequence for compression, vasoconstrictors, TXA, cautery and packing?...
Annals Journal Watch
From the specialty flagship
One recent paper from Annals of Emergency Medicine worth knowing on shift, chosen for practice impact — independent of today’s topics.
Mattson AE, Spolsdoff D, Brown CS, et al. · PMID 42841836
This ED comparative study asks whether cephalosporin generation affects outcomes in patients discharged with pyelonephritis. It targets a common prescribing decision where antibiotic choice and reliable follow-up matter.
Bottom line → Before discharging a patient with pyelonephritis on a cephalosporin, check local susceptibility guidance and ensure a plan to review the urine culture.
Critical Care Corner
Matched to today’s topics
A critical-care reference from LITFL’s Critical Care Compendium, tied to today’s differential.
Anaphylaxis is a resuscitation diagnosis: rapidly evolving airway edema, bronchospasm, or hypotension demands treatment before every feature is present.
Anaphylaxis is a severe, life-threatening, generalised or systemic hypersensitivity reaction. It is characterised by rapidly developing life-threatening airway (pharyngeal or laryngeal edema) and/or breathing (bronchospasm and tachypnea) and/or circulation (hypotension and tachycardia) problems usually associated with skin and mucosal changes
Pharmacology Corner
Two drugs for the shift
One antimicrobial and one other ED workhorse — selected daily, with sources and last-reviewed dates so every dose is cross-checkable.
Antimicrobial of the Day
Cefdinir
Third-generation oral cephalosporin
Indication
Acute otitis media, acute bacterial sinusitis, community-acquired pneumonia, pharyngitis, and uncomplicated SSTI when an oral cephalosporin is appropriate.
What’s your dose? — reveal dosing & cautions
ED Dose
300 mg PO q12h or 600 mg PO once daily x5–10 days. Pediatric: 14 mg/kg/day (max 600 mg/day) divided q12–24h.
Renal Adjustment
CrCl < 30 mL/min: 300 mg PO once daily. HD: 300 mg every other day.
Contraindications
Cephalosporin hypersensitivity.
Interactions
Iron and aluminum/magnesium antacids reduce absorption — separate by ≥ 2 h. Probenecid increases levels.
Monitoring
GI tolerance; clinical response.
ED Pearl
Co-administration with iron causes harmless brick-red stools from a non-absorbable iron–cefdinir complex — reassure the family rather than working it up as a GI bleed.
Vasodilatory hypotension with tachyarrhythmia concerns, procedural/peri-intubation hypotension, and selected anesthesia-related hypotension; not preferred for most septic shock.
What’s your dose? — reveal dosing & cautions
ED Dose
Infusion: 0.1–0.5 mcg/kg/min, titrate to MAP. Push-dose: commonly 50–200 mcg IV aliquots using institution-approved premixed concentration.
Renal Adjustment
No renal adjustment; titrate to effect.
Contraindications
Severe hypertension, ventricular tachycardia. Relative caution in cardiogenic shock/poor cardiac output due to afterload increase.
Interactions
MAOIs/TCAs may potentiate; beta-blockers may worsen reflex bradycardia; oxytocics may intensify hypertension.
ED Pearl
Phenylephrine may make the number look better while worsening cardiac output; in shock, ask whether the patient needs squeeze, heart rate support, or actual forward flow.
For educational use only. Verify dosing against the FDA label and your institution’s pharmacy resources before administering.
ECG of the Day
Rhythm
Idiopathic Fascicular Ventricular Tachycardia
A relatively narrow, RBBB-pattern VT with left axis deviation in a young, healthy patient is fascicular VT — verapamil-sensitive, and misdiagnosed as SVT with aberrancy at your peril.
The Tracing
A 28-year-old man with no medical history presents with palpitations and lightheadedness that started at rest. He is alert and talking, blood pressure 108/70. The monitor shows a regular broad-complex tachycardia, but the QRS looks oddly narrow for a wide-complex rhythm — around 120 ms. There is an RBBB morphology with an RSR' in V1 and marked left axis deviation. Running the lead II rhythm strip, you catch occasional P waves that march through independently, and one beat mid-strip is suddenly narrow and early. The rate is fast and sustained, and he has had brief episodes like this before that resolved on their own.
Monomorphic VT with signs of AV dissociation, fusion complexes, or capture beats
QRS duration 100-140 ms — narrower than other forms of VT
Short RS interval (onset of R to nadir of S) of 60-80 ms, versus > 100 ms in most VT
RBBB pattern (RSR' in V1)
Axis deviation by subtype: left axis deviation in the common posterior fascicular VT (90-95%), right axis in anterior fascicular VT
Pearls
Fascicular VT is the most common idiopathic VT of the left ventricle, arising by re-entry near the left posterior fascicle in structurally normal hearts — typically young patients, 15-40 years, 60-80% male.
The whole game is proving it is VT and not SVT with RBBB: look for dissociated P waves, a narrow capture beat, or fusion complexes on a rhythm strip before you commit.
It is verapamil-sensitive and characteristically does not respond to adenosine, vagal maneuvers, or lidocaine — so a rhythm that ignores adenosine is a clue, not a failure.
Pitfalls
The relatively narrow QRS and RBBB+LAD pattern is routinely mislabeled SVT with bifascicular block; missing the AV dissociation means missing that this is VT.
An identical-looking fascicular VT can be driven by digoxin toxicity via enhanced automaticity — in that setting the treatment is digoxin immune Fab, not verapamil.
Do not reflexively reach for the usual VT drugs: this rhythm is often unresponsive to lidocaine, and treating it as ordinary VT wastes time.
At the Bedside
In a stable patient, once you have confirmed VT, verapamil is first-line and often terminates it. If there is any suspicion of digoxin toxicity, give digoxin immune Fab instead; treat the unstable patient with electrical cardioversion.
For educational use only. Verify ECG interpretation against the LITFL entry and your institution’s practice before clinical decision-making.
Case of the Day
From the lead · Anaphylaxis Update
Self-Examination
Test Your Understanding
A patient develops diffuse urticaria, hoarseness, and hypotension minutes after eating. What is the best immediate intervention?
AIV diphenhydramine
BIM epinephrine
CIV corticosteroid
DNebulized albuterol
Reveal answer
Correct answer · B
IM epinephrine is first-line for anaphylaxis with airway or circulatory compromise and must not be delayed for IV access or adjuncts. Antihistamines and albuterol may help selected symptoms but do not treat shock or upper-airway edema.
Study Pace4 topics today; Issue 86 of 94 — Hematology and Oncology (Weeks 47-48)Deadline · June 1, 2026